VNDA M&A Bids
Cycle Pharmaceuticals Doubles Down on Bid to Acquire $VNDA
➯ All-cash offer at $8/share
» 80% premium to VNDA’s share price at close on 10/11/24
» $488M fully diluted equity value
➯ Proposal made public after VNDA board’s refusal to engage on initial offer
$VNDA Confirms Receipt of Cycle's Proposal
➯ Determines to not be in the best interest of company or stockholders
➯ Stock up by 18% at open (10/14/24) following the offer
💡 Become an Elite subscriber today and quickly find answers to these key questions:
How many of the top 34 biopharma-focused hedge funds hold each of these tickers?
How many months of cash do they have?
What are the main differences in the most shorted biopharma companies that are widely held vs. not widely held by top biopharma hedge funds?
And more...
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 10/16/24 JD, AV, & EJV